TEPZZ _7 8 6A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2017/22

Size: px
Start display at page:

Download "TEPZZ _7 8 6A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2017/22"

Transcription

1 (19) TEPZZ _7 8 6A_T (11) EP A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: Bulletin 17/22 (1) Int Cl.: G02B 1/04 (06.01) C09B 69/ (06.01) (21) Application number: (22) Date of filing: (84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: MA MD (71) Applicant: Pegavision Corporation Taoyuan City 333 (TW) Yu, Hsiao-Ting Taoyuan City (TW) Chang, Han-Yi Taoyuan City (TW) Lai, Yu-Chin Taoyuan City (TW) (74) Representative: Zimmermann & Partner Patentanwälte mbb Josephspitalstr München (DE) (72) Inventors: Chiang, Te-Ju Taoyuan City (TW) (4) HYDROGEL COMPOSITION AND HYDROGEL CONTACT LENSES MADE OF THE COMPOSITION (7) A hydrogel composition and a hydrogel contact lens made of the hydrogel composition are provided. The hydrogel composition includes a hydrophilic monomer, a blue light-blocking monomer, a crosslinker and an initiator. The hydrophilic monomer is in a range from to parts by weight. The blue light-blocking monomer is in a range from 0.02 to 0. parts by weight and has a yellow dye. The crosslinker is in a range from 0.1 to 1 parts by weight. The initiator is in a range from 0.2 to 2 parts by weight. EP A1 Printed by Jouve, 7001 PARIS (FR)

2 Description BACKGROUND Field of Disclosure [0001] The present disclosure relates to a hydrogel composition. More particularly, the present disclosure relates to a blue light-blocking hydrogel composition. Description of Related Art 1 [0002] Since contact lenses made of hydrogel have good moisturizing capabilities, hydrogel contact lenses can provide sufficient water content to cornea even wearing them for a long time and improve the uncomfortable symptoms of eyes caused by the dryness of cornea. Therefore, hydrogel has become one of the preferred components of contact lenses. [0003] A lot of electronic display devices such as television screens, computer monitors, tablets, mobile phones have used a light emitting diode (LED) as a light source for twenty years. It is well known that blue light, which is characterized by a wavelength of nanometers (nm) and emitted from the LED, easily causes eye diseases. In the case of prolonged use of tablet or mobile phone may damage retina, and further induce the early development of cataract and macular degeneration because eyes are prolonged exposure to blue light. [0004] In the current market, however, there is a lack of contact lenses which can block blue light and have a high water content. Therefore, it is essential for manufacturing a hydrogel contact lens which can block blue light and have a high water content. 2 3 SUMMARY [000] In view of the issue un-met in the art, the present disclosure provides a hydrogel composition which can block blue light, and a hydrogel contact lens made of the hydrogel composition may have a high water content and blue lightblocking efficacy. [0006] The present disclosure provides a hydrogel composition for manufacturing a hygrogel contact lens. The hydrogel composition includes a hydrophilic monomer, a blue light-blocking monomer, a crosslinker and an initiator. The hydrophilic monomer is in a range from to parts by weight. The blue light-blocking monomer is in a range from 0.02 to 0. part by weight and has a yellow dye. The crosslinker is in a range from 0.1 to 1 part by weight. The initiator is in a range from 0.2 to 2 parts by weight. [0007] In various embodiments of the present disclosure, the hydrophilic monomer is in a range from 96. to parts by weight. [0008] In various embodiments of the present disclosure, the hydrogel composition further includes a silicone component selected from a group consisting of a silicone monomer, a silicone macromer and a silicone prepolymer, and in which the silicone component is in a range from to 9 parts by weight, and the hydrophilic monomer is in a range from to 60 parts by weight. [0009] In various embodiments of the present disclosure, the silicone monomer has a structure of formula (1): 4 0 which V 1 is 2

3 L 1 is a C3 C7 alkylene group or 1 and R 1 is a methyl group or 2 which * is a linkage position of V 1, L 1 and R 1 in the structure of formula (1). [00] In various embodiments of the present disclosure, the silicone macromer has a structure of formula (2): which L 2 is a C3 C alkylene group, 3 4 and S 2 is 0 which R 2 is C3 C alkyl group, n is an integer from 2 to 4, and * is a linkage position of V 2 and S 2 in the structure of formula (2). [0011] In various embodiments of the present disclosure, the silicone prepolymer has a structure of formula (3): 3

4 which V 3 is 1 L 3 is a C2 C alkylene group, and m is an integer from to 0, which * is a linkage position of V 3 in the structure of formula (3). [0012] In various embodiments of the present disclosure, the yellow dye has a structure of formula (4): 2 which R 3 is -OH or -CH 3, and R 4 is -O- or -CH 2 CH 2 NH-. [0013] In various embodiments of the present disclosure, when R 3 is -OH and R 4 is -CH 2 CH 2 NH- in the structure of formula (4), the yellow dye has a structure of formula (): 3 [0014] In various embodiments of the present disclosure, when R 3 is -CH 3 and R 4 is -O- in the structure of formula (4), the yellow dye has a structure of formula (6): 4 0 [001] In various embodiments of the present disclosure, the yellow dye has a sulfonyl group or a sulfonate group. 4

5 [0016] In various embodiments of the present disclosure, when the yellow dye has the sulfonyl group, the yellow dye has a structure of formula (7): 1 2 [0017] In various embodiments of the present disclosure, when the yellow dye has the sulfonate group, the yellow dye has a structure of formula (8): 3 [0018] In various embodiments of the present disclosure, the yellow dye has an amide group. [0019] In various embodiments of the present disclosure, when the yellow dye has the amide group, the yellow dye has a structure of formula (9): 4 0 [00] In various embodiments of the present disclosure, the hydrophilic monomer is selected from a group consisting of N-vinyl pyrrolidone (NVP), 2-hydroxyethyl methacrylate (HEMA), glyceryl methacrylate (GM), methacrylic acid, acrylic acid, N,N-dimethyl acrylamide (DMA), N,N-dimethyl methacrylamide and N-vinyl-N-methyl acetamide. [0021] In various embodiments of the present disclosure, the crosslinker is selected from a group consisting of ethylene glycol dimethacrylate, diethylene glycol dimethacrylate, triethylene glycol dimethacrylate, tetraethylene glycol dimeth-

6 1 2 3 acrylate, ally dimethacrylate, ethylene glycol dially ether, triethylene glycol dially ether, tetraethylene glycol dially ether, triallyl-s-triazine-2,4,6(1h,3h,h)-trione and 1,1,1 -trimethylolpropane trimethacrylate. [0022] In various embodiments of the present disclosure, the initiator is a photoinitiator. [0023] In various embodiments of the present disclosure, the photoinitiator is a phosphine-oxide-based initiator, a titanium metallocene-based initiator or a combination thereof. [0024] In various embodiments of the present disclosure, the phosphine-oxide-based initiator is selected from a group consisting of diphenyl (2,4,6-triphenyl)phosphine oxide, bis(2,4,6-trimethylbenzoyl)phenyl phosphine oxide and bis(2,6- dimethoxylbenzoyl)(2,4,4-trimethylpentyl) phosphine oxide. [002] In various embodiments of the present disclosure, the titanium metallocene-based initiator comprises dicyclopentadienyl bis[2,4-difluoro-3-(1-pyrrolyl) phenyl] titanium. [0026] In various embodiments of the present disclosure, the hydrogel composition further includes an UV-blocking monomer in a range from 0. to 2 parts by weight. [0027] In various embodiments of the present disclosure, the UV-blocking monomer has benzophenone, benzotriazole or a combination thereof. [0028] In various embodiments of the present disclosure, when the UV-blocking monomer has benzophenone, the UV-blocking monomer is selected from a group consisting of 4-methacryloxy-2-hydroxy benzophenone and 4-(2-acryloxyethoxy-2-hydroxy benzophenone. [0029] In various embodiments of the present disclosure, when the UV-blocking monomer has benzotriazole, the UVblocking monomer is selected from a group consisting of 2-(2-hydroxy--methacryloxyethylphenyl)-2H-benzotriazole, 2-(2-hydroxy--methacryloxyethylphenyl)-2H-6-chloro-benzotriazole, 2-(2-hydroxy--methacryloxyethylphenyl)-2H- 6- methoxybenzotriazole, 2-[3 -t-butyl- -(3"-dimethylvinylsilylpropoxy)-2 -hydroxyphenyl]--methoxybenzo triazole, 2-[3 - t-butyl- -(3"-methacryloylozypropyl)phenyl]--chlorobenzotriazole and 2-[2 -hydroxy- -(γ-methacryloyloxypropoxy)-3 - tert-butylphenyl]--methoxy-2h-benzotriazole. [00] In various embodiments of the present disclosure, the hydrogel composition further includes a hydrophobic monomer in a range from 1 to parts by weight. [0031] In various embodiments of the present disclosure, the hydrophobic monomer is selected from a group consisting of methyl methacrylate, butyl methacrylte, n-hexyl methacrylate and isobornyl methacrylate. [0032] In various embodiments of the present disclosure, the hydrogel composition further includes an organic solvent in a range from 1 to parts by weight. [0033] In various embodiments of the present disclosure, the organic solvent is selected from a group consisting of glycerol, n-butanol, t-butanol, t-amyl alcohol and n-hexanol. [0034] The present disclosure also provides a hydrogel contact lens. The hydrogel contact lens includes a contact lens body made of the hydrogel composition stated above. [003] These and other features, aspects, and advantages of the present disclosure will become better understood with reference to the following description and appended claims. [0036] It is to be understood that both the foregoing general description and the following detailed description are by examples, and are intended to provide further explanation of the invention as claimed. 4 0 DETAILED DESCRIPTION [0037] Reference will now be made in detail to the present embodiments of the invention, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers are used in the drawings and the description to refer to the same or like parts. [0038] The following embodiments are disclosed for detailed description. For illustration clarity, many details of practice are explained in the following descriptions. However, it should be understood that these details of practice do not intend to limit the present invention. That is, these details of practice are not necessary in parts of embodiments of the present invention. Furthermore, for simplifying the drawings, some of the conventional structures and elements are shown with schematic illustrations. [0039] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms "comprises" and/or "comprising", or "includes" and/or "including" or "has" and/or "having" when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof. [00] As aforementioned problems, it is noted that eyes prolonged exposure to blue light are easy to cause eye diseases. However, while full blockage of blue light can offer the best protection of eyes, it may cause poor vision, especially during the evening. Therefore, how to manufacture a hydrogel contact lens which can simultaneously protect 6

7 1 eyes and maintain a good vision, especially in the evening, is still an issue un-met in the art. [0041] In view of the issue un-met in the art, the present disclosure provides a hydrogel composition for manufacturing a hygrogel contact lens. A hydrogel contact lens made of the hydrogel composition can block blue light partially to protect eyes and has a clear vision even during evening. [0042] The present disclosure provides a hydrogel composition for manufacturing a hygrogel contact lens. The hydrogel composition includes a hydrophilic monomer, a blue light-blocking monomer, a crosslinker and an initiator. The hydrophilic monomer is in a range from to parts by weight. The blue light-blocking monomer is in a range from 0.02 to 0. part by weight and has a yellow dye. The crosslinker is in a range from 0.1 to 1 partby weight. The initiator is in a range from 0.2 to 2 parts by weight. [0043] In various embodiments of the present disclosure, the hydrophilic monomer is in a range from 96. to parts by weight. [0044] For instance, the hydrophilic monomer is selected from a group consisting of N-vinyl pyrrolidone (NVP), 2- hydroxyethyl methacrylate (HEMA), glyceryl methacrylate (GM), methacrylic acid, acrylic acid, N,N-dimethyl acrylamide (DMA), N,N-dimethyl methacrylamide and N-vinyl-N-methyl acetamide. [004] In various embodiments of the present disclosure, the hydrogel composition further includes a silicone component selected from a group consisting of a silicone monomer, a silicone macromer and a silicone prepolymer. When the hydrogel composition includes a silicone component, the hydrogel composition includes the silicone component in a range from to 9 parts by weight, the hydrophilic monomer in a range from to 60 parts by weight, the blue lightblocking monomer in a range from 0.02 to 0. part by weight and has a yellow dye, the crosslinker in a range from 0.1 to 1 part by weight and the initiator in a range from 0.2 to 2 parts by weight. [0046] Specifically, the silicone component may be selected from a group consisting of a silicone monomer, a silicone macromer and a silicone prepolymer. The silicone monomer, the silicone macromer and the silicone prepolymer may be selected from various components listed in Table

8 Silicone monomer 1 Table

9 (continued) Silicone macromer

10 (continued) Silicone prepolymer [0047] In various embodiments of the present disclosure, the yellow dye may be a component which have an ethylenically- based polymerizable group, a sulfonyl group, a sulfonate group and an amide group, as shown in Table 2. The yellow dye having the ethylenically- Structure 1 Table 2 3 based polymerizable group Structure 2 4 0

11 (continued) The yellow dye having the sulfonyl group Structure 3 1 The yellow dye having the sulfonate group Structure The yellow dye having the amide group Structure 4 0 [0048] In various embodiments of the present disclosure, the crosslinker is selected from a group consisting of ethylene glycol dimethacrylate, diethylene glycol dimethacrylate, triethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, ally dimethacrylate, ethylene glycol dially ether, triethylene glycol dially ether, tetraethylene glycol dially ether, triallyl-s-triazine-2,4,6(1h,3h,h)-trione and 1,1,1 -trimethylolpropane trimethacrylate. [0049] In various embodiments of the present disclosure, the initiator is a photoinitiator. The photoinitiator is a phosphine-oxide-based initiator, a titanium metallocene-based initiator or a combination thereof. [000] In various embodiments of the present disclosure, the phosphine-oxide-based initiator is selected from a group consisting of diphenyl (2,4,6-triphenyl)phosphine oxide, bis(2,4,6-trimethylbenzoyl)phenyl phosphine oxide and bis(2,6- dimethoxylbenzoyl)(2,4,4-trimethylpentyl) phosphine oxide. [001] In various embodiments of the present disclosure, the titanium metallocene-based initiator comprises dicyclopentadienyl bis[2,4-difluoro-3-(1-pyrrolyl) phenyl] titanium. [002] In various embodiments of the present disclosure, the hydrogel composition further includes an UV-blocking monomer in a range from 0. to 2 parts by weight. The UV-blocking monomer has benzophenone, benzotriazole or a combination thereof. [003] In various embodiments of the present disclosure, when the UV-blocking monomer has benzophenone, the UV-blocking monomer is selected from a group consisting of 4-methacryloxy-2-hydroxy benzophenone and 4-(2-acry- 11

12 1 2 3 loxyethoxy-2-hydroxy benzophenone. [004] In various embodiments of the present disclosure, when the UV-blocking monomer has benzotriazole, the UVblocking monomer is selected from a group consisting of 2-(2-hydroxy--methacryloxyethylphenyl)-2H-benzotriazole, 2-(2-hydroxy--methacryloxyethylphenyl)-2H-6-chloro-benzotriazole, 2-(2-hydroxy--methacryloxyethylphenyl)-2H- 6- methoxybenzotriazole, 2-[3 -t-butyl- -(3"-dimethylvinylsilylpropoxy)-2 -hydroxyphenyl]--methoxybenzo triazole, 2-[3 - t-butyl- - (3"-methacryloylozypropyl)phenyl]--chlorobenzotriazole and 2-[2 -hydroxy- -(γ-methacryloyloxypropoxy)-3 - tert-butylphenyl]--methoxy-2h-benzotriazole. [00] In various embodiments of the present disclosure, the hydrogel composition further includes a hydrophobic monomer in a range from 1 to parts by weight. The hydrophobic monomer is selected from a group consisting of methyl methacrylate, butyl methacrylte, n-hexyl methacrylate and isobornyl methacrylate. [006] In various embodiments of the present disclosure, the hydrogel composition further includes an organic solvent in a range from 1 to parts by weight. The organic solvent is selected from a group consisting of glycerol, n-butanol, t-butanol, t-amyl alcohol and n-hexanol. [007] The hydrogel composition stated above was filled into and between two polypropylene molds, and cured under visible light to fabricate a hydrogel contact lens. The hydrogel contact lens was subsequently dry-released from molds and extracted with hot water. After being extracted with hot water, the hydrogel contact lens was placed in the polypropylene blister package filled with borate buffered saline. The polypropylene blister package was sealed with aluminum foil and autoclaved at 1 C for minutes. [008] The hydrogel contact lens made by the manufacturing method stated above has a water content in a range of 38 80%, preferably 70%, and can also block % blue light which is characterized by a wavelength of nanometers (nm). [009] The following hydrogel compositions are only exemplary, but not intended to limit the present disclosure. Specifically, each of the hydrogel compositions 1 8 includes 2-hydroxyethyl methacrylate (HEMA) 9 parts by weight, methacrylic acid 1.9 parts by weight, ethylene glycol dimethacrylate 0.8 part by weight, 1,1,1-trimethylolpropane trimethacrylate 0.1 part by weight, bis(2,4,6-trimethylbenzoyl)phenyl phosphine oxide 0. part by weight, 2-(2-hydroxy-- methacryloxyethylphenyl)-2h-benzotriazole 1.0 part by weight, a reactive blue dye 19 (RB19) 0.03 part by weight and a yellow dye with different structures and amount as shown in Table 3. Table 3 shows the transmittance of blue light ( nm) of the hydrogel contact lenses made of the hydrogel compositions 1 8. Table 3 Hydrogel compositions 1 (Control) Yellow dye with structure 1 (parts by weight) Yellow dye with structure 2 (parts by weight) Yellow dye with structure 4 (parts by weight) Yellow dye with structure (parts by weight) Transmittance of blue light (%) 98% 60% 4% 80% % 8% 7% 0% Blockage of blue light (%) 0 % % % 4% 1% 2% 0% 4 0 [0060] As shown in Table 3, when the yellow dye of the hydrogel compositions is in a range from 0.02 to 0.1 part by weight, the transmittance of blue light of the hydrogel contact lenses made of the hydrogel compositions 1 8 are 4 8%. In other words, the hydrogel contact lenses can block 1 % blue light. Accordingly, users can prevent their eyes from the damage of blue light and have a clear vision, even during the evening, while wearing the hydrogel contact lenses made of the hydrogel compositions 1 8. [0061] Then, visual acuity and contract sensitivity of the comprehensive tests were performed. The quantity of letters which can be correctly identified by the subjects under different environmental conditions (sun light, regular room light and dim light) and contrast were also measured [0062] The above tests were performed by subjects who are between 2 years old. The visual acuity of the subjects was /2 while wearing their habitual contact lenses, in which the "/2" means that ordinary people can see a visual target at 2 feet, but the subjects can only see the visual target at feet. First, subjects respectively wore hydrogel contact lenses (experimental contact lenses) and normal contact lenses (control contact lenses), in which the hydrogel contact lenses (experimental contact lenses) were made of the hydrogel composition 7 stated above were with 2% blockage of blue light. In contrast, the normal contact lenses (control contact lenses) could not block the blue light. Furthermore, the experimental contact lenses and the control contact lenses both had the same base curve and diameter. Next, the subjects were evaluated for visual acuity and contrast sensitivity by identifying 60 test letters at 4-meter distance 12

13 under the different environmental conditions (sun light, regular room light and dim light) and the different contrast levels about the colors of letters and background. The quantity of letters that could be correctly identified reflects the visual acuity and the contrast sensitivity of the subjects, and the results (p < 0.0) are shown in Table Table 4 Sun light (^8,000 Lux) Experimental contact lens (with 2% blockage of blue light) Control contact lens High contrast (0%) Medium contrast (%) Low contrast (2.%) Regular room light (190 6 Lux) Experimental contact lens (with 2% blockage of blue light) Control contact lens High contrast (0%) Medium contrast (%) Low contrast (2.%) Dim light ( Lux) Experimental contact lens (with 2% blockage of blue light) Control contact lens High contrast (0%) Medium contrast (%) Low contrast (2.%) [0063] As a result, no matter under sun light, regular room light or dim light, and high contrast, medium contrast or low contrast, the experimental contact lenses with 2% blockage of blue light does not affect the subjects to correctly identify letters. Further, while wearing the experimental contact lenses, the subjects can correctly identify more quantity of letters than wearing the control contact lenses, and have better visual acuity and contrast sensitivity. Even wearing the experimental contact lenses in the dim light environment, the subjects still have better visual acuity and contrast sensitivity. [0064] The embodiments of the present disclosure discussed above have advantages over existing contact lens, and the advantages are summarized below. The hydrogel contact lens made of the hydrogel composition in the present disclosure can block % blue light to protect eyes from exposing to the harmful blue light, and further prevent eye diseases such as cataract and macular degeneration. In addition, the hydrogel contact lens made of the hydrogel composition of the present disclosure do not affect but even improve the visual acuity and the contract sensitivity of the users. Therefore, the users wearing the hydrogel contact lens provided by the present disclosure can have a good vision even under the dim light. [006] Although the present invention has been described in considerable detail with reference to certain embodiments thereof, other embodiments are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein. [0066] It will be apparent to those skilled in the art that various modifications and variations can be made to the structure of the present invention without departing from the scope or spirit of the invention. In view of the foregoing, it is intended that the present invention cover modifications and variations of this invention provided they fall within the scope of the following claims. 0 Claims 1. A hydrogel composition for manufacturing a hygrogel contact lens, the hydrogel composition comprising: a hydrophilic monomer in a range from to parts by weight; a blue light-blocking monomer in a range from 0.02 to 0. part by weight and having a yellow dye; a crosslinker in a range from 0.1 to 1 part by weight; and 13

14 an initiator in a range from 0.2 to 2 parts by weight. 2. The hydrogel composition of claim 1, wherein the hydrophilic monomer is in a range from 96. to parts by weight. 3. The hydrogel composition of Claim 1, further comprising a silicone component selected from a group consisting of a silicone monomer, a silicone macromer and a silicone prepolymer, and wherein the silicon component is in a range from to 9 parts by weight, and the hydrophilic monomer is in a range from to 60 parts by weight. 4. The hydrogel composition of claim 3, wherein the silicone monomer has a structure of formula (1): 1 2 wherein V 1 is or 3 L 1 is a C3 C7 alkylene group or 4 0 and R 1 is a methyl group or 14

15 wherein * is a linkage position of V 1, L 1 and R 1 in the structure of formula (1).. The hydrogel composition of claim 3, wherein the silicone macromer has a structure of formula (2): 1 wherein L 2 is a C3 C alkylene group, 2 3 and S 2 is 4 wherein R 2 is C3 C alkyl group, n is an integer from 2 to 4, and * is a linkage position of V 2 and S 2 in the structure of formula (2). 6. The hydrogel composition of claim 3, wherein the silicone prepolymer has a structure of formula (3): 0 wherein V 3 is 1

16 or 1 L 3 is a C2 C alkylene group, and m is an integer from to 0, wherein * is a linkage position of V 3 in the structure of formula (3). 7. The hydrogel composition of claim 1, wherein the yellow dye has a structure of formula (4): 2 wherein R 3 is -OH or -CH 3, and R 4 is -O- or -CH 2 CH 2 NH-. 8. The hydrogel composition of claim 7, wherein when R 3 is -OH and R 4 is -CH 2 CH 2 NH- in the structure of formula (4), the yellow dye has a structure of formula (): The hydrogel composition of claim 7, wherein when R 3 is -CH 3 and R 4 is -O- in the structure of formula (4), the yellow dye has a structure of formula (6): 0 16

17 1. The hydrogel composition of claim 1, wherein the yellow dye has a sulfonyl group or a sulfonate group. 11. The hydrogel composition of claim, wherein when the yellow dye has the sulfonyl group, the yellow dye has a structure of formula (7): The hydrogel composition of claim, wherein when the yellow dye has the sulfonate group, the yellow dye has a structure of formula (8): The hydrogel composition of claim 1, wherein the yellow dye has an amide group. 14. The hydrogel composition of claim 13, wherein when the yellow dye has the amide group, the yellow dye has a 17

18 structure of formula (9): The hydrogel composition of claim 1, wherein the hydrophilic monomer is selected from a group consisting of N- vinyl pyrrolidone (NVP), 2-hydroxyethyl methacrylate (HEMA), glyceryl methacrylate (GM), methacrylic acid, acrylic acid, N,N-dimethyl acrylamide (DMA), N,N-dimethyl methacrylamide and N-vinyl-N-methyl acetamide. 16. The hydrogel composition of claim 1, wherein the crosslinker is selected from a group consisting of ethylene glycol dimethacrylate, diethylene glycol dimethacrylate, triethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, ally dimethacrylate, ethylene glycol dially ether, triethylene glycol dially ether, tetraethylene glycol dially ether, triallyl-s-triazine-2,4,6(1h,3h,h)-trione and 1,1,1 -trimethylolpropane trimethacrylate. 17. The hydrogel composition of claim 1, wherein the initiator is a photoinitiator. 18. The hydrogel composition of claim 17, wherein the photoinitiator is a phosphine-oxide-based initiator, a titanium metallocene-based initiator or a combination thereof. 19. The hydrogel composition of claim 18, wherein the phosphine-oxide-based initiator is selected from a group consisting of diphenyl (2,4,6-triphenyl)phosphine oxide, bis(2,4,6-trimethylbenzoyl)phenyl phosphine oxide and bis(2,6-dimethoxylbenzoyl)(2,4,4-trimethylpentyl) phosphine oxide. 3. The hydrogel composition of claim 18, wherein the titanium metallocene-based initiator comprises dicyclopentadienyl bis[2,4-difluoro-3-(1-pyrrolyl) phenyl] titanium. 21. The hydrogel composition of claim 1, further comprising an UV-blocking monomer in a range from 0. to 2 parts by weight. 22. The hydrogel composition of claim 21, wherein the UV-blocking monomer has benzophenone, benzotriazole or a combination thereof The hydrogel composition of claim 22, wherein when the UV-blocking monomer has benzophenone, the UV-blocking monomer is selected from a group consisting of 4-methacryloxy-2-hydroxy benzophenone and 4-(2-acryloxyethoxy- 2-hydroxy benzophenone The hydrogel composition of claim 22, wherein when the UV-blocking monomer has benzotriazole, the UV-blocking monomer is selected from a group consisting of 2-(2-hydroxy--methacryloxyethylphenyl)-2H-benzotriazole, 2-(2- hydroxy--methacryloxyethylphenyl)-2h-6-chloro-benzotriazole, 2-(2-hydroxy--methacryloxyethylphenyl)-2H- 6- methoxybenzotriazole, 2-[3 -t-butyl- -(3"-dimethylvinylsilylpropoxy)-2 -hydroxyphenyl]--methoxybenzo triazole, 2-[3 -t-butyl- - (3"-methacryloylozypropyl)phenyl]--chlorobenzotriazole and 2-[2 -hydroxy- -(γ-methacryloyloxypropoxy)-3 -tert-butylphenyl]--methoxy-2h-benzotriazole. 2. The hydrogel composition of claim 1, further comprising a hydrophobic monomer in a range from 1 to parts by weight. 26. The hydrogel composition of claim 2, wherein the hydrophobic monomer is selected from a group consisting of methyl methacrylate, butyl methacrylte, n-hexyl methacrylate and isobornyl methacrylate. 18

19 27. The hydrogel composition of claim 1, further comprising an organic solvent in a range from 1 to parts by weight. 28. The hydrogel composition of claim 27, wherein the organic solvent is selected from a group consisting of glycerol, n-butanol, t-butanol, t-amyl alcohol and n-hexanol. 29. A hydrogel contact lens, comprising: a contact lens body made of the hydrogel composition of any of claim 1 to

20

21

TEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006.

TEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006. (19) TEPZZ _784 A_T (11) EP 3 17 842 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 07.06.17 Bulletin 17/23 (1) Int Cl.: A61K 9/00 (06.01) A61K 31/439 (06.01) (21) Application number: 1197874.9

More information

TEPZZ 85_Z 4A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION

TEPZZ 85_Z 4A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION (19) TEPZZ 8_Z 4A_T (11) EP 2 81 034 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 2.03.1 Bulletin 1/13 (21) Application number: 1022.2 (1) Int Cl.: A61C /02 (06.01) A61C 19/04 (06.01)

More information

TEPZZ _ 849 A_T EP A1 (19) (11) EP A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art.

TEPZZ _ 849 A_T EP A1 (19) (11) EP A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art. (19) TEPZZ _ 849 A_T (11) EP 3 138 493 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 3(4) EPC (43) Date of publication: 08.03.17 Bulletin 17/ (21) Application number: 786271. (22)

More information

EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2011/42

EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2011/42 (19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 377 14 A2 (43) Date of publication: 19..11 Bulletin 11/42 (21) Application number: 10329.0 (1) Int Cl.: A61K 9/00 (06.01) A61K 31/13 (06.01) A61K 31/167

More information

(51) Int Cl.: A61K 9/20 ( ) A61K 31/41 ( )

(51) Int Cl.: A61K 9/20 ( ) A61K 31/41 ( ) (19) TEPZZ 94677_A_T (11) (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 2.11.1 Bulletin 1/48 (1) Int Cl.: A61K 9/ (06.01) A61K 31/41 (06.01) (21) Application number: 116790.3 (22) Date of

More information

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2012/28

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2012/28 (19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 474 288 A1 (43) Date of publication: 11.07.2012 Bulletin 2012/28 (51) Int Cl.: A61F 2/40 (2006.01) A61F 2/30 (2006.01) (21) Application number: 11150615.0

More information

TEPZZ Z697_5A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/20 ( ) A61K 31/135 (2006.

TEPZZ Z697_5A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/20 ( ) A61K 31/135 (2006. (19) TEPZZ Z697_A_T (11) EP 3 069 7 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 21.09.16 Bulletin 16/38 (1) Int Cl.: A61K 9/ (06.01) A61K 31/13 (06.01) (21) Application number: 160172.1

More information

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'

More information

*EP A1* EP A1 (19) (11) EP A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art.

*EP A1* EP A1 (19) (11) EP A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art. (19) Europäisches Patentamt European Patent Office Office européen des brevets *EP00147089A1* (11) EP 1 47 089 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 18(3) EPC (43) Date

More information

(51) Int Cl.: A61K 9/00 ( ) A61K 31/198 ( ) A61K 47/26 ( )

(51) Int Cl.: A61K 9/00 ( ) A61K 31/198 ( ) A61K 47/26 ( ) (19) TEPZZ 8Z6B_T (11) EP 2 8 06 B1 (12) EUROPEAN PATENT SPECIFICATION (4) Date of publication and mention of the grant of the patent: 08.06.16 Bulletin 16/23 (21) Application number: 1171684.2 (22) Date

More information

EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/16

EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/16 (19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 047 749 A2 (43) Date of publication: 1.04.09 Bulletin 09/16 (21) Application number: 0838028.0 (22) Date of filing: 07..08 (84) Designated Contracting States:

More information

EP A1 (19) (11) EP A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC

EP A1 (19) (11) EP A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (19) (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 13(4) EPC (11) EP 2 07 001 A1 (43) Date of publication: 01.07.2009 Bulletin 2009/27 (21) Application number: 07834499.1 (22) Date

More information

Supporting Information

Supporting Information Supporting Information IG TRUGPUT DISCVERY F EW FULIG-RESISTAT SURFACES Mingyan Zhou, ongwei Liu, Adith Venkiteshwaran, James Kilduff, Daniel G. Anderson, Robert Langer and Georges Belfort J. Mater. Chem.,

More information

*EP A1* EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2004/12

*EP A1* EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2004/12 (19) Europäisches Patentamt European Patent Office Office européen des brevets *EP001398311A1* (11) EP 1 398 311 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 17.03.04 Bulletin 04/12 (1)

More information

Pharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH

Pharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI - Comparative Analysis PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI Conference Vienna, 29 June 2007 PPRI Conference, Vienna, 29 June 2007 1 Comparative Analysis - Outline

More information

Calypso Application. License for card and portable objects.

Calypso Application. License for card and portable objects. Calypso Application License for card and portable objects. I N N O V A T R O N CalypsoLicense page 1 / 6 Innovatron, 27 rue de Bassano, 75008 Paris, France 1. License Policy General Presentation Innovatron

More information

TEPZZ Z9Z74_A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION

TEPZZ Z9Z74_A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION (19) TEPZZ Z9Z74_A_T (11) EP 3 090 741 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 09.11.2016 Bulletin 2016/4 (21) Application number: 1642039.1 (1) Int Cl.: A61K 31/203 (2006.01) A61K

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

Consequence of the change in the definition of. an agricultural parcel

Consequence of the change in the definition of. an agricultural parcel Ispra, 03-04 April 2008 Kick-off Meeting of the 2008 CwRS Campaign 1 Consequence of the change in the definition of Andrew ROWLANDS MARS-PAC, JRC Ispra an agricultural parcel Ispra, 03-04 April 2008 Kick-off

More information

Photobiology And The Human Eye:

Photobiology And The Human Eye: Photobiology And The Human Eye: What Eye Care Providers Should Know About UV and Blue Light Protection Dr. Gary Heiting, OD April 10, 2016 INTRODUCTION As scientific knowledge about the health effects

More information

FDA > CDRH > CFR Title 21 Database Search

FDA > CDRH > CFR Title 21 Database Search Page 1 of 10 FDA Home Page CDRH Home Page Search CDRH A-Z Index Contact CDRH 510(k) Registration Listing Adverse Events PMA Classification CLIA CFR Title 21 Advisory Committees Assembler Recalls Guidance

More information

(12) Patent Application Publication (10) Pub. No.: US 2009/ A1

(12) Patent Application Publication (10) Pub. No.: US 2009/ A1 (19) United States US 2009.02451 05A1 (12) Patent Application Publication (10) Pub. No.: US 2009/0245105 A1 HO (43) Pub. Date: Oct. 1, 2009 (54) METHOD FOR NETWORK TRANSMISSION (30) Foreign Application

More information

United States Patent (11) 3,615,595. Assistant Examiner-Stephen B. Davis Attorney-Cushman, Darby and Cushman

United States Patent (11) 3,615,595. Assistant Examiner-Stephen B. Davis Attorney-Cushman, Darby and Cushman United States Patent (11) 72 21) (22) (73) 54 52) (51) Inventor Alvin Guttag Bethesda, Md. Appl. No. 814,271 Filed Apr. 8, 1969 Patented Oct. 26, 1971 Assignee National Patent Development Corporation New

More information

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government

More information

Enhanced safety in breast implants

Enhanced safety in breast implants Enhanced safety in breast implants Introduction Despite significant improvements in implant quality, rupture of breast implants is still possible If leak is suspected: Detection by palpation Experienced

More information

Palliative nursing care of children and young people across Europe

Palliative nursing care of children and young people across Europe Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)

More information

(43) Publication date: 04 September 2014 ( ) (22) Filing Date: 27 February 2014 ( )

(43) Publication date: 04 September 2014 ( ) (22) Filing Date: 27 February 2014 ( ) (54) Title (EN): INCOHERENT TYPE-III MATERIALS FOR CHARGE CARRIERS CONTROL DEVICES (54) Title (FR): MATÉRIAUX DE TYPE III INCOHÉRENTS POUR DISPOSITIFS DE RÉGULATION DE PORTEURS DE CHARGES (72) Inventor(s):

More information

EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2012/28

EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2012/28 (19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 474 278 A2 (43) Date of publication: 11.07.2012 Bulletin 2012/28 (1) Int Cl.: A61B 17/80 (2006.01) (21) Application number: 1210644.8 (22) Date of filing:.01.2012

More information

(12) United States Patent (10) Patent No.: US 6,691,578 B1

(12) United States Patent (10) Patent No.: US 6,691,578 B1 USOO6691578B1 (12) United States Patent (10) Patent No.: US 6,691,578 B1 Puskas (45) Date of Patent: Feb. 17, 2004 (54) MEASUREMENT SYSTEMS FOR 4,710,233 A 12/1987 Hohmann et al.... 205/701 ULTRASOUND

More information

INNOVATION THAT REALLY MATTERS. Prof. Lina Badimon. Institut Català de Ciències Cardiovasculars (ICCC), Barcelona

INNOVATION THAT REALLY MATTERS. Prof. Lina Badimon. Institut Català de Ciències Cardiovasculars (ICCC), Barcelona INNOVATION THAT REALLY MATTERS Prof. Lina Badimon, Barcelona THE INSTITUTION THE INSTITUTION THE ICCC CATALAN INSTITUTE FOR CARDIOVASCULAR SCIENCE (ICCC) Objectives LEADING AN STRATEGIC PLANNING IN CVR

More information

Attention. Therefore, all the data and statements made in this presentation are preliminary and might change in the future.

Attention. Therefore, all the data and statements made in this presentation are preliminary and might change in the future. Attention The aim of the Dose Datamed II workshop in Athens was to present preliminary data, collect feedback from the audience and to work towards final results and conclusions. Therefore, all the data

More information

(12) Patent Application Publication (10) Pub. No.: US 2009/ A1

(12) Patent Application Publication (10) Pub. No.: US 2009/ A1 (19) United States US 20090305855A1 (12) Patent Application Publication (10) Pub. No.: US 2009/0305855A1 Terre (43) Pub. Date: Dec. 10, 2009 (54) ABDOMINAL EXERCISE MACHINE (57) ABSTRACT An abdominal exercise

More information

(12) Patent Application Publication (10) Pub. No.: US 2008/ A1

(12) Patent Application Publication (10) Pub. No.: US 2008/ A1 US 2008.0092779A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0092779 A1 Wang et al. (43) Pub. Date: Apr. 24, 2008 (54) ULTRAVIOLET ABSORBER FORMULATION (30) Foreign Application

More information

Ulllted States Patent [19] [11] Patent Number: 4,997,881

Ulllted States Patent [19] [11] Patent Number: 4,997,881 Ulllted States Patent [19] [11] Patent Number: 4,997,881 Patel et a1. [45] Date of Patent: Mar. 5, 1991 [54] POLY(ALKYL VINYL ETHER)POLYOLEFIN [56] References Cited COPOLYMERS U.S. PATENT DOCUMENTS [75]

More information

(43) International Publication Date. 15 July 2010 ( ) WO 2010/ A3. (19) World Intellectual Property Organization International Bureau

(43) International Publication Date. 15 July 2010 ( ) WO 2010/ A3. (19) World Intellectual Property Organization International Bureau (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International

More information

LIMITE EN COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /11 LIMITE ENFOPOL 228 DAPIX 81

LIMITE EN COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /11 LIMITE ENFOPOL 228 DAPIX 81 COUNCIL OF THE EUROPEAN UNION Brussels, 7 July 2011 12390/11 LIMITE ENFOPOL 228 DAPIX 81 NOTE From: Presidency To: Law Enforcement Working Party No. prev. doc.: CM 1508/11 Subject: Results of the questionnaire

More information

(12) United States Patent

(12) United States Patent USOO894762OB2 (12) United States Patent Kuo et al. (54) BROADBAND CHOLESTERIC LIQUID CRYSTAL FILM, METHOD FOR FABRICATING THE SAME, POLARIZATION DEVICE, AND HIGH LIGHT EFFICIENCY LIQUID CRYSTAL DISPLAY

More information

2H-Azepin-2-one, 1-ethenylhexahydro

2H-Azepin-2-one, 1-ethenylhexahydro Chemical Name CAS number URL Benzoic acid, 2- phenylethyl ester 94-47-3 https://echa.europa.eu/registration-dossier/-/registered-dossier/19730 2H-Azepin-2-one, 1-ethenylhexahydro- 2235-00-9 https://echa.europa.eu/registration-dossier/-/registered-dossier/13517

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Spreading Excellence and Widening Participation

Spreading Excellence and Widening Participation Spreading Excellence and Widening Participation Dr G Ambroziewicz Ankara, 27/02/2017 Research and Background Disparities in research and innovation performance: barrier to competitiveness, growth and jobs

More information

(81) Designated States (unless otherwise indicated, for every

(81) Designated States (unless otherwise indicated, for every (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International

More information

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11

More information

02009R1223 EN

02009R1223 EN ANNEX VI LIST OF UV FILTERS ALLOWED IN COSMETIC PRODUCTS CAS EC M1 1 2 N,N,N-Trimethyl-4-(2- oxoborn-3-ylidenemethyl) anilinium methyl sulfate Camphor Benzalkonium Methosulfate 52793-97-2 258-190-8 6 %

More information

EURL-SRM - Analytical Observations Report

EURL-SRM - Analytical Observations Report concerning the following EURL-SRM - Analytical Observations Report o Compound(s): AMTT (metabolite of tritosulfuron) o Commodities: Fruit and vegetables, cereals o Extraction Method(s): o Instrumental

More information

WO 2012/ A3. 15 November 2012 ( ) P O P C T

WO 2012/ A3. 15 November 2012 ( ) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International

More information

Transmission, processing and publication of HBS 2015 data

Transmission, processing and publication of HBS 2015 data EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics Unit F-4: Income and living conditions; Quality of life Doc. LC-ILC/194/17/EN estat.f.4 (2017) WORKING GROUP ON INCOME AND LIVING CONDITIONS

More information

(12) Patent Application Publication (10) Pub. No.: US 2006/ A1

(12) Patent Application Publication (10) Pub. No.: US 2006/ A1 (19) United States US 2006O115435A1 (12) Patent Application Publication (10) Pub. No.: US 2006/0115435 A1 Wilkens (43) Pub. Date: (54) DENTAL TOOTHPASTE, SOLUTION, TABLET AND SYSTEM WITH PLAOUE COLOR INDICATOR

More information

Item 2.2 Household definition

Item 2.2 Household definition EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics Doc. DSSB/2016/Jun/2.2 Item 2.2 Household definition MEETING OF THE BOARD OF THE EUROPEAN DIRECTORS OF SOCIAL STATISTICS LUXEMBOURG, 28 AND

More information

Results of the Survey addressed to the EU Member States about quantification of food waste and preventing Food waste Brussels,

Results of the Survey addressed to the EU Member States about quantification of food waste and preventing Food waste Brussels, Results of the Survey addressed to the EU Member States about quantification of food waste and preventing Food waste Brussels, 29.11.2016 Survey Number of addressed countries: 29 28 (EU Member States)

More information

(12) Patent Application Publication (10) Pub. No.: US 2014/ A1

(12) Patent Application Publication (10) Pub. No.: US 2014/ A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0166282 A1 Martinez et al. US 20140166282A1 (43) Pub. Date: (54) (71) (72) (73) (21) (22) (60) FUNCTIONALIZED HYDROGEN SULFIDE

More information

When do I submit a technology disclosure? When you have identified an invention that is commercially attractive

When do I submit a technology disclosure? When you have identified an invention that is commercially attractive Lee Samuel PhD CPA When do I submit a technology disclosure? When you have identified an invention that is commercially attractive But when do you know you have an invention? Timeline of a Patent Time

More information

Report from the CMD(h) meeting held on 17 th and 18 th March 2008

Report from the CMD(h) meeting held on 17 th and 18 th March 2008 Report from the CMD(h) meeting held on 17 th and 18 th March 2008 CMD(h)/EMEA Sub-Group on Paediatric Regulation Further to the line listings received for authorised medicinal products (including purely

More information

Esters with Improved Hydroalcoholic Solubility. Posted February 15, 2008

Esters with Improved Hydroalcoholic Solubility. Posted February 15, 2008 Esters with Improved Hydroalcoholic Solubility Tony O Lenick Siltech LLC tolenick@mindspring.com Kevin O Lenick SurfaTech Corporation kevin@surfatech.com Posted February 15, 2008 www.surfatech.com Background

More information

Funded by EAHC (tender EAHC/2012/Health/06 - Lot 2) Cooperation between GfK Belgium (contractor) and RAND Europe (advisor) 1

Funded by EAHC (tender EAHC/2012/Health/06 - Lot 2) Cooperation between GfK Belgium (contractor) and RAND Europe (advisor) 1 STATE OF PLAY IN THE USE OF ALCOHOLIC BEVERAGE LABELS TO INFORM CONSUMERS ABOUT HEALTH ASPECTS ACTION TO PREVENT AND REDUCE HARM FROM ALCOHOL Sara Gysen GfK Belgium, Public Services Funded by EAHC (tender

More information

TEPZZ 76 5Z A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION

TEPZZ 76 5Z A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION (19) TEPZZ 76 Z A_T (11) EP 2 762 02 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 06.08.14 Bulletin 14/32 (21) Application number: 1410886.1 (1) Int Cl.: C08F 2/18 (06.01) C09D 133/08

More information

(12) Patent Application Publication (10) Pub. No.: US 2009/ A1

(12) Patent Application Publication (10) Pub. No.: US 2009/ A1 US 20090287233A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0287233 A1 Huculak (43) Pub. Date: Nov. 19, 2009 (54) SMALL GAUGE MECHANICAL TISSUE Publication Classification

More information

Oy Publication number:

Oy Publication number: Europaisches Patentamt J European Patent Office Office europeen des brevets Oy Publication number: 0 468 564 A2 EUROPEAN PATENT APPLICATION Application number: 91201723.3 Date of filing: 04.07.91 int.

More information

RC4-1. User s instructions RC4-1 remote control

RC4-1. User s instructions RC4-1 remote control RC4-1 User s instructions RC4-1 remote control The remote control and any other parts shown in these user s instructions may not look the same as the one(s) you have. We furthermore reserve the right to

More information

Modifiers and Retransmitters (Secondary Light Sources)

Modifiers and Retransmitters (Secondary Light Sources) Vision and Light Vision Generators Transmitters (Light Sources) Modifiers and Retransmitters (Secondary Light Sources) Receivers Decoder Encoders Interpreter (Eyes) (Brain) Sun, Discharge lamps, fluorescent

More information

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11

More information

At-A-Glance report 2013

At-A-Glance report 2013 At-A-Glance report 213 Cystic Fibrosis in Europe Facts and Figures 213 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic

More information

1 ADJUSTMENT THRESHOLD-N. United States Patent (19) Donehoo et al. 5,660,184. Aug. 26, 1997 PATIENT'S HEARTBEAT PACEMAKEREVENT QRS DETECTION THRESHOLD

1 ADJUSTMENT THRESHOLD-N. United States Patent (19) Donehoo et al. 5,660,184. Aug. 26, 1997 PATIENT'S HEARTBEAT PACEMAKEREVENT QRS DETECTION THRESHOLD United States Patent (19) Donehoo et al. US00566O184A 11 Patent Number: 45 Date of Patent: 5,660,184 Aug. 26, 1997 54 PACEMAKER PULSE DETECTION AND ARTIFACT REJECTION 75 Inventors: Robert F. Donehoo, Lutz;

More information

Key findings of the 2016 EMN Focused Study on Family Reunification of Third-Country Nationals in the EU plus Norway

Key findings of the 2016 EMN Focused Study on Family Reunification of Third-Country Nationals in the EU plus Norway Key findings of the 2016 EMN Focused Study on Family Reunification of Third-Country Nationals in the EU plus Norway Nataliya Nikolova EMN Service Provider (ICF) icfi.com Presentation overview Objectives

More information

(12) United States Patent

(12) United States Patent USOO951 0624B2 (12) United States Patent Li et al. (10) Patent No.: (45) Date of Patent: US 9,510,624 B2 Dec. 6, 2016 (54) DISPOSABLE ELECTRONIC CIGARETTE (75) Inventors: Yonghai Li, Shenzhen (CN); Zhongli

More information

Non-reproductive tissues and cells

Non-reproductive tissues and cells Colour key Minimum requirements as set out in Directive 2004/23/EC and its technical Directives (particularly 2006/17/EC) More stringent -legally binding, applies for all donations and all donor profiles

More information

(12) Patent Application Publication (10) Pub. No.: US 2017/ A1

(12) Patent Application Publication (10) Pub. No.: US 2017/ A1 (19) United States US 2017.0099889A1 (12) Patent Application Publication (10) Pub. No.: US 2017/0099889 A1 LOU (43) Pub. Date: (54) HIGH STRESS RETENTION NITRILE (52) U.S. Cl. GLOVE CPC... A41D 19/0082

More information

Matrix-induced Signal Enhancement of Propamocarb in LC-MS/MS

Matrix-induced Signal Enhancement of Propamocarb in LC-MS/MS Observations concerning a compound a matrix a method other Matrix-induced Signal Enhancement of Propamocarb in LC-MS/MS Reported by: EURL-SRM Version 1 (last update: 24.10.2012) Brief description of problem/observation/solution:

More information

Porta Potti Qube Campa Potti Qube User Manual

Porta Potti Qube Campa Potti Qube User Manual Porta Potti Qube Campa Potti Qube User Manual QUICK GUIDE Preparing waste-holding tank 1 2 3 QUICK GUIDE Emptying waste-holding tank 10 11 12 4 5 6 13 14 15 Preparing flush-water tank Emptying flush-water

More information

Photoinitiators for Water Based UV Curing. Sink or Swim? W. A. Green. Ex Great Lakes Fine Chemicals.

Photoinitiators for Water Based UV Curing. Sink or Swim? W. A. Green. Ex Great Lakes Fine Chemicals. Photoinitiators for Water Based UV Curing. Sink or Swim? W. A. Green. Ex Great Lakes Fine Chemicals. ag@arthurgreen.cc Why water based UV? Two main parameters that provide advantage: Very low viscosity

More information

'SECTION B EU PARTY. The following abbreviations are used:

'SECTION B EU PARTY. The following abbreviations are used: 'SECTION B EU PARTY The following abbreviations are used: AT Austria BE Belgium BG Bulgaria CY Cyprus CZ Czech Republic DE Germany DK Denmark ES Spain EE Estonia EU European Union, including all its Member

More information

(12) Patent Application Publication (10) Pub. No.: US 2015/ A1

(12) Patent Application Publication (10) Pub. No.: US 2015/ A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0113348 A1 Douskey et al. US 2015O113348A1 (43) Pub. Date: Apr. 23, 2015 (54) (71) (72) (73) (21) (22) IMPLEMENTING MISR COMPRESSION

More information

Patient reporting update

Patient reporting update Patient reporting update François Houÿez Director of Treatment Information & Access, EURORDIS 8 th Pharmacovigilance stakeholders forum EMA, 15/06/2014 15/09/2014 eurordis.org 1 Spontaneous reporting in

More information

EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY

EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2016)5909621-13/10/2016 EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY Directorate B - Health systems, medical products and innovation B4 Medical products: quality, safety

More information

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014 Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack

More information

TEPZZ A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2016/04

TEPZZ A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2016/04 (19) TEPZZ 976946A_T (11) (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 27.01.16 Bulletin 16/04 (21) Application number: 1180902.7 (22) Date of filing:..11 (1) Int Cl.: A01N 3/02 (06.01) A01N

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animedazon Spray, 2.45 % w/w cutaneous spray suspension for cattle, sheep and pigs (AT, BE, BG, CZ, CY, DE, DK, EL, ES, FR,

More information

Trends in injecting drug use in Europe

Trends in injecting drug use in Europe Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information

More information

Do you want your lenses with or without blue light protection?

Do you want your lenses with or without blue light protection? Do you want your lenses with or without blue light protection? The most complete near-clear protection against blue light. Potential Benefits* Relief From Digital Eye Strain Filters Light without distorting

More information

Vision/Lifestyle Questionnaire

Vision/Lifestyle Questionnaire Roger J. Meyer, M.D. Retina Fellowship Trained Macular Degeneration Diabetic Eye Care Glaucoma Robert M. Reinauer, M.D. Retina Fellowship Trained Surgical/Medical Treatment of the Retina & Vitreous Macular

More information

At-A-Glance report 2014

At-A-Glance report 2014 At-A-Glance report 14 Cystic Fibrosis in Europe Facts and Figures 14 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic

More information

EU School Fruit, Vegetables & Milk Scheme 2017/2023

EU School Fruit, Vegetables & Milk Scheme 2017/2023 EU School Fruit, Vegetables & Milk Scheme 2017/2023 What's new High Level Group on Nutrition and Physical Activities Brussels, 29/11/2017 AGRI.G.3 What's new since last High Level Group meeting By 31/7/2017

More information

Implementation of Smoke-free laws in the EU: Measures by Member State (Situation as of June 2009)

Implementation of Smoke-free laws in the EU: Measures by Member State (Situation as of June 2009) MS Scope of current regulation Entry into force Further developments 1. Total protection in all enclosed workplaces and public places (smoking banned altogether) IE Ban on smoking in all enclosed workplaces

More information

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria

More information

Official Journal of the European Union REGULATIONS

Official Journal of the European Union REGULATIONS L 30/2 6.2.2015 REGULATIONS COMMISSION REGULATION (EU) 2015/174 of 5 February 2015 amending and correcting Regulation (EU) No 10/2011 on plastic materials and articles intended to come into contact with

More information

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Ref. Ares(2015)2319265-03/06/2015 EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Directorate D - Health systems and products D4 Substances of Human Origin and Tobacco Control Brussels,

More information

Improving Headphone Fit Using Design Of Cable

Improving Headphone Fit Using Design Of Cable Technical Disclosure Commons Defensive Publications Series October 27, 2017 Improving Headphone Fit Using Design Of Cable N/A Follow this and additional works at: http://www.tdcommons.org/dpubs_series

More information

Suitability of (Meth)acrylates for Use in Sealant Applications

Suitability of (Meth)acrylates for Use in Sealant Applications Suitability of (Meth)acrylates for Use in Sealant Applications James E. Goodrich Sartomer USA, LLC 2 Thomas Jones Way Exton, PA, USA 19341 Abstract The use of (meth)acrylates in peroxide or amine cured

More information

CHEMICALS THAT CAN FORM EXPLOSIVE PEROXIDES

CHEMICALS THAT CAN FORM EXPLOSIVE PEROXIDES 1 of 6 Chemicals that can form explosive peroxides can be divided into three classes, depending on the risk they pose and the length of time for which they have been stored. You should be aware that the

More information

New trends in harm reduction in Europe: progress made challenges ahead

New trends in harm reduction in Europe: progress made challenges ahead New trends in harm reduction in Europe: progress made challenges ahead Dagmar Hedrich, Alessandro Pirona, EMCDDA 2 nd European Harm Reduction Conference, 7-9 May 2014, Basel Session 4: Changes in harm

More information

Screening programmes for Hepatitis B/C in Europe

Screening programmes for Hepatitis B/C in Europe Programme STI, HIV/AIDS and viral hepatitis Screening programmes for Hepatitis B/C in Europe Mika Salminen, Ph.D. European Centre for Disease Prevention and Control Why might screening be needed for hepatitis

More information

Nanopigments For Broad Spectrum Sun Protection. Patricia Aikens NAFTA Technical Services

Nanopigments For Broad Spectrum Sun Protection. Patricia Aikens NAFTA Technical Services Nanopigments For Broad Spectrum Sun Protection Patricia Aikens NAFTA Technical Services UV radiation and the skin UV absorbers Nanopigments Titanium dioxide Zinc Oxide Electromagnetic Radiation Longer

More information

(12) Patent Application Publication (10) Pub. No.: US 2008/ A1

(12) Patent Application Publication (10) Pub. No.: US 2008/ A1 US 20080082047A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0082047 A1 Harmon (43) Pub. Date: Apr. 3, 2008 (54) VEIN HOLDER (52) U.S. Cl.... 604/115 (76) Inventor: Stoney

More information

Public Assessment Report Scientific discussion. Ibuprofen 400 mg/100 ml solution for infusion & Ibuprofen 600 mg/100 ml solution for infusion

Public Assessment Report Scientific discussion. Ibuprofen 400 mg/100 ml solution for infusion & Ibuprofen 600 mg/100 ml solution for infusion Public Assessment Report Scientific discussion Ibuprofen 400 mg/100 ml solution for infusion & Ibuprofen 600 mg/100 ml solution for infusion Ibuprofen arginine ES/H/0390/001/DC ES/H/0392/001/DC Applicant:

More information

CLINICAL RESEARCH METHODS VISP356. MODULE LEADER: PROF A TOMLINSON B.Sc./B.Sc.(HONS) OPTOMETRY

CLINICAL RESEARCH METHODS VISP356. MODULE LEADER: PROF A TOMLINSON B.Sc./B.Sc.(HONS) OPTOMETRY DIVISION OF VISION SCIENCES SESSION: 2005/2006 DIET: 1ST CLINICAL RESEARCH METHODS VISP356 LEVEL: MODULE LEADER: PROF A TOMLINSON B.Sc./B.Sc.(HONS) OPTOMETRY MAY 2006 DURATION: 2 HRS CANDIDATES SHOULD

More information

WO 2016/ Al. 20 October 2016 ( ) P O P C T

WO 2016/ Al. 20 October 2016 ( ) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International

More information

...d. EEEEEEE/EE/EE. (12) Patent Application Publication (10) Pub. No.: US 2008/ A1. (19) United States

...d. EEEEEEE/EE/EE. (12) Patent Application Publication (10) Pub. No.: US 2008/ A1. (19) United States (19) United States US 200802684.85A1 (12) Patent Application Publication (10) Pub. No.: US 2008/0268485 A1 Guarino et al. (43) Pub. Date: Oct. 30, 2008 (54) ICONIC DISPLAY OF MARKERS FOR A METER (76) Inventors:

More information

UK National Aerospace NDT Board

UK National Aerospace NDT Board UK National Aerospace NDT Board c/o The British Institute of NDT Newton Building, St George s Avenue Northampton, NN2 6JB United Kingdom Tel: +44 (0)1604-893-811. Fax: +44 (0)1604-893-868. E-mail: Nicole.scutt@bindt.org

More information

(12) United States Patent (10) Patent No.: US 6,365,596 B1

(12) United States Patent (10) Patent No.: US 6,365,596 B1 USOO63696B1 (12) United States Patent (10) Patent No.: US 6,365,596 B1 Valenti (45) Date of Patent: Apr. 2, 2002 (54) ORAL PHARMACEUTICAL COMPOSITIONS (51) Int. Cl."... A61K 31/44 CONTAINING BUPRENORPHIN

More information

March 19, 1957 J. T. PATTON, JR 2,786,080 STABILIZED POLYOXYALKYLENE COMPOSITIONS

March 19, 1957 J. T. PATTON, JR 2,786,080 STABILIZED POLYOXYALKYLENE COMPOSITIONS March 19, 1957 J. T. PATTON, JR STABILIZED POLYOXYALKYLENE COMPOSITIONS Filed Nov. 25, 1953 FIGURE I 2 Sheets-Sheet l PERCENT CARBONYL DEVELOPED IN POLYOXYALKYLENE COMPOUNDS AT OO C. 3. Polyoxypropylene

More information

SDIVISION. Attorney Docket No Date: 14 May 2008

SDIVISION. Attorney Docket No Date: 14 May 2008 SDIVISION DEPARfMENT OF THE NAVY NAVAL UNDERSEA WARFARE CENTER NEWPORT OFFICE OF COUNSEL PHONE: (401) 832-3653 FAX: (401) 832-4432 NEWPORT DSN: 432-3653 Attorney Docket No. 95764 Date: 14 May 2008 The

More information